{"id":122305,"date":"2021-07-19T19:30:00","date_gmt":"2021-07-19T19:30:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=28932462893246"},"modified":"2021-07-19T19:30:00","modified_gmt":"2021-07-19T19:30:00","slug":"increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/","title":{"rendered":"Increasing incidence of hematological and genetic disorders in both developed and developing countries fuels the demand for Adeno-Associated Virus (AAV) Vectors in Gene Therapy"},"content":{"rendered":"<p><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/07\/5353-new20logo-01-2.png\" class=\"webfeedsFeaturedVisual wp-post-image\" alt=\"\" loading=\"lazy\" style=\"display: block; margin-bottom: 5px; clear:both;max-width: 100%;\" link_thumbnail=\"\" \/><\/p>\n<p><span style=\"font-weight: 400;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/beta-kiosk.icrowdnewswire.com\/assets\/source\/users\/delveinsight\/Adeno-Associated-Virus-Vectors.jpg?1626699340433\" alt=\"Adeno-Associated-Virus-Vectors\" \/><\/span><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight\u2019s <\/span><a href=\"https:\/\/www.delveinsight.com\/report-store\/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=spr\"><strong>Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline report<\/strong><\/a><span style=\"font-weight: 400;\"> provides in-depth analysis of the current clinical development landscape and growth prospects for Adeno-Associated Virus (AAV) Vectors in Gene Therapy.<\/span><\/p>\n<p><strong>Some of the Crucial Highlights from the <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=spr\"><strong>AAV Vectors in Gene Therapy Pipeline Report<\/strong><\/a><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">AAV particles are made up of single-stranded DNA encased in a protein shell. Despite their basic structure, recombinant AAVs (rAAV) can play a critical role in nucleic acid delivery to cells.<\/span><\/li>\n<li style=\"font-weight: 400;\"><strong>uniQure, Lysogene, Spark Therapeutics, MeiraGTx, Advernum Biotechnologies, Rocket Pharmaceuticals <\/strong><span style=\"font-weight: 400;\">are among the major companies which are active in the AAV Vectors in Gene Therapy market.<\/span><\/li>\n<li style=\"font-weight: 400;\"><strong>Etranacogene dezaparvovec <\/strong><span style=\"font-weight: 400;\">is a pipeline AAV Vectors Gene Therapy which is in the Phase III of clinical trials while <\/span><strong>LYS-SAF302 <\/strong><span style=\"font-weight: 400;\">pipeline AAV Vectors Gene Therapy is in the Phase II\/III of development.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Some pipeline AAV Vectors Gene Therapies such as <\/span><strong>AAV2-hCHM and AAV CNGA3 <\/strong><span style=\"font-weight: 400;\">are in the Phase I\/II stage of development.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">There are also some pipeline AAV Vectors Gene Therapies such as <\/span><strong>ADVM 022 and RP L401,\u00a0 <\/strong><span style=\"font-weight: 400;\">which are still in the early stage of development i.e. Phase I of clinical trials.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Request sample @ <\/span><a href=\"https:\/\/www.delveinsight.com\/sample-request\/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=spr\"><strong>AAV Vectors in Gene Therapy Pipeline Report<\/strong><\/a><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=spr\"><strong>Adeno-Associated Virus Overview<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">Humans and certain other primate species are infected with Adeno-Associated Viruses (AAVs), which are tiny viruses. They are members of the <\/span><em><span style=\"font-weight: 400;\">Dependoparvovirus<\/span><\/em><span style=\"font-weight: 400;\"> genus, which is part of the Parvoviridae family. AAV is not known to cause disease at this time. The viruses elicit only a minor immune response. AAV has a number of other characteristics that make it a good choice for generating viral vectors for gene therapy and isogenic human disease models.<\/span><\/p>\n<p><strong>AAV Vectors in Gene Therapy Pipeline Analysis: Drug Profile<\/strong><\/p>\n<p><strong>AAV-CNGA3: MeiraGTx<\/strong><\/p>\n<p><span style=\"font-weight: 400;\">Subretinal injection of AAV-CNGA3, a gene therapy treatment meant to restore cone function, is used to deliver AAV-CNGA3 to the cone receptors in the back of the eye. It was created with a synthetic promoter linked to high gene expression to accommodate for the higher amount of protein required to restore cone function in individuals with achromatopsia (ACHM) due to a CNGA3 gene mutation.<\/span><\/p>\n<p><strong>AAV Vectors in Gene Therapy Pipeline Therapies and Key Players<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Etranacogene dezaparvovec: uniQure<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">LYS-SAF302: Lysogene<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">AAV2-hCHM: Spark Therapeutics<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">AAV CNGA3: MeiraGTx<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">ADVM 022: Advernum Biotechnologies<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">RP L401: Rocket Pharmaceuticals<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Learn more about AAV @ <\/span><a href=\"https:\/\/www.delveinsight.com\/report-store\/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=spr\"><strong>AAV Vectors in Gene Therapy Major Companies<\/strong><\/a><\/p>\n<p><strong>AAV Vectors in Gene Therapy Therapeutics Assessment<\/strong><\/p>\n<ul>\n<li><strong>By Product Type<\/strong><\/li>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Monotherapy<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Combination Therapy<\/span><\/li>\n<\/ul>\n<li><strong>By Stage<\/strong><\/li>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Discovery<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Pre-Clinical<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Phase I<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Phase II<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Phase III<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Pre-registration<\/span><\/li>\n<\/ul>\n<\/ul>\n<ul>\n<li><strong>By Route of Administration<\/strong>\n<ul>\n<li><strong><span style=\"font-weight: 400;\">Inhalation<\/span><\/strong><\/li>\n<li><strong><span style=\"font-weight: 400;\">Intravenous<\/span><\/strong><\/li>\n<li><span style=\"font-weight: 400;\">Oral<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Subcutaneous<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li><strong><strong>By Molecule Type<\/strong><\/strong>\n<ul>\n<li><span style=\"font-weight: 400;\">Small Molecule<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Monoclonal Antibody<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Proteins<\/span><\/li>\n<\/ul>\n<\/li>\n<li><strong>By Indications<\/strong>\n<ul>\n<li>Solid Tumors<\/li>\n<\/ul>\n<ul>\n<li>Bladder Cancer\u00a0<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li>Inactive Product Analysis\n<ul>\n<li><span style=\"font-weight: 400;\">Dormant<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>Discontinued\u00a0<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><strong>Scope of the Report<\/strong><\/p>\n<p><strong>Coverage:<\/strong><span style=\"font-weight: 400;\"> Global<\/span><\/p>\n<p><strong>AAV Vectors in Gene Therapy Key Players: <\/strong><span style=\"font-weight: 400;\">uniQure, Lysogene, Spark Therapeutics, MeiraGTx, Advernum Biotechnologies, Rocket Pharmaceuticals,<\/span> <span style=\"font-weight: 400;\">among others<\/span><\/p>\n<p><strong>AAV Vectors in Gene Therapy Pipeline Therapies: <\/strong><span style=\"font-weight: 400;\">Etranacogene dezaparvovec, ADVM 022, LYS-SAF302, AAV2-hCHM, AAV CNGA3, RP L401, and others<\/span><\/p>\n<p><strong>Table of Contents<\/strong><\/p>\n<table style=\"border-collapse: collapse; width: 100%;\" border=\"1\">\n<tbody>\n<tr>\n<td style=\"width: 9.21569%;\">1.<\/td>\n<td style=\"width: 90.7843%;\"><span style=\"font-weight: 400;\">Introduction<\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 9.21569%;\">2.<\/td>\n<td style=\"width: 90.7843%;\"><span style=\"font-weight: 400;\">Executive Summary<\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 9.21569%;\">3.<\/td>\n<td style=\"width: 90.7843%;\"><span style=\"font-weight: 400;\">Adeno-Associated Virus (AAV) Vectors in Gene Therapy: Overview<\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 9.21569%;\">4.<\/td>\n<td style=\"width: 90.7843%;\"><span style=\"font-weight: 400;\">AAV Vectors in Gene Therapy Competitive Landscape \u2013 Active Drugs<\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 9.21569%;\">5.<\/td>\n<td style=\"width: 90.7843%;\"><span style=\"font-weight: 400;\">AAV Vectors in Gene Therapy Pipeline Therapeutics<\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 9.21569%;\">6.<\/td>\n<td style=\"width: 90.7843%;\"><span style=\"font-weight: 400;\">AAV Vectors in Gene Therapy Late Stage Products<\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 9.21569%;\">7.<\/td>\n<td style=\"width: 90.7843%;\"><span style=\"font-weight: 400;\">AAV Vectors in Gene Therapy Mid Stage Products<\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 9.21569%;\">8.<\/td>\n<td style=\"width: 90.7843%;\"><span style=\"font-weight: 400;\">AAV Vectors in Gene Therapy Early\u00a0 Stage Products<\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 9.21569%;\">9.<\/td>\n<td style=\"width: 90.7843%;\"><span style=\"font-weight: 400;\">AAV Vectors in Gene Therapy Therapeutic Assessment<\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 9.21569%;\">10.<\/td>\n<td style=\"width: 90.7843%;\"><span style=\"font-weight: 400;\">AAV Vectors in Gene Therapy Inactive Products<\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 9.21569%;\">11.<\/td>\n<td style=\"width: 90.7843%;\"><span style=\"font-weight: 400;\">Appendix<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">Know more of what\u2019s covered in the <\/span><a href=\"https:\/\/www.delveinsight.com\/sample-request\/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=spr\"><strong>AAV Vectors in Gene Therapy Pipeline Assessment Report<\/strong><\/a><\/p>\n<p><strong>Key questions answered in the AAV Vectors in Gene Therapy Pipeline Report<\/strong><\/p>\n<ul>\n<li><strong><span style=\"font-weight: 400;\">What are the current AAV Vectors in Gene Therapy treatment options?<\/span><\/strong><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">How many AAV Vectors in Gene Therapy developing therapies are in the early, mid, or late stages of development for AAV Vectors in Gene Therapy treatment?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">What are the reasons for AAV Vectors in Gene Therapy\u00a0 inactive and discontinued products?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">How many patents for developing therapeutics for the treatment of AAV Vectors in Gene Therapy have been awarded or are pending?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">What are the major designations for Adeno-Associated Virus (AAV) Vectors in Gene Therapy that have been granted?<\/span><\/li>\n<\/ul>\n<p><strong>Related Reports<\/strong><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=spr\"><strong>Non-Small-Cell Lung Cancer Pipeline Insights<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight\u2019s, <\/span><strong>\u201cNon-Small-Cell Lung cancer (NSCLC) \u2013 Pipeline Insight, 2021,\u201d<\/strong><span style=\"font-weight: 400;\"> report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape.<\/span><strong>\u00a0<\/strong><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/advanced-liver-cancer-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=spr\"><strong>Advanced Liver Cancer Pipeline Insights<\/strong><\/a><\/p>\n<p><strong>\u201cAdvanced liver cancer Pipeline Insights, 2021\u201d<\/strong><span style=\"font-weight: 400;\"> report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Advanced liver cancer market.\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/sample-request\/relapsed-or-refractory-myelodysplastic-syndrome-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=spr\"><strong>Relapsed or Refractory Myelodysplastic Syndrome Pipeline Insights<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">Get comprehensive analysis of <\/span><span style=\"font-weight: 400;\">Relapsed or Refractory Myelodysplastic Syndrome<\/span><span style=\"font-weight: 400;\"> pipeline therapies and key companies including such as <\/span><strong>Novartis, BioTheryX, Cantex Pharmaceuticals, Agios Pharmaceuticals, <\/strong><span style=\"font-weight: 400;\">among others.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/bladder-cancer-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=spr\"><strong>Bladder cancer Pipeline Insights<\/strong><\/a><\/p>\n<p><strong>\u201cBladder cancer Pipeline Insights, 2021\u201d<\/strong><span style=\"font-weight: 400;\"> report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Bladder cancer market.\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/sample-request\/lymphatic-malformations-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=spr\"><strong>Lymphatic Malformations Pipeline Insights<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">Get comprehensive analysis of <\/span><span style=\"font-weight: 400;\">Lymphatic Malformations<\/span><span style=\"font-weight: 400;\"> pipeline therapies and key companies including <\/span><strong>Vanthera, Cerecor, Inc., Protara therapeutics,<\/strong><span style=\"font-weight: 400;\"> among others.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/sample-request\/necrobiosis-lipoidica-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=spr\"><strong>Necrobiosis Lipoidica Pipeline Insights<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">Get comprehensive analysis of <\/span><span style=\"font-weight: 400;\">Necrobiosis Lipoidica<\/span><span style=\"font-weight: 400;\"> pipeline therapies and key companies including <\/span><strong>Novartis, Processa Pharmaceuticals,<\/strong><span style=\"font-weight: 400;\"> among others.<\/span><span style=\"font-weight: 400;\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/cervical-cancer-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=spr\"><strong>Cervical Cancer Pipeline Insights<\/strong><\/a><\/p>\n<p><strong>\u201cCervical Cancer Pipeline Insights, 2021\u201d<\/strong><span style=\"font-weight: 400;\"> report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Cervical Cancer market.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/gastric-cancer-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=spr\"><strong>Gastric Cancer Pipeline Insights<\/strong><\/a><\/p>\n<p><strong>\u201cGastric Cancer Pipeline Insights, 2021\u201d <\/strong><span style=\"font-weight: 400;\">report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Gastric Cancer market.\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/central-nervous-system-lymphoma-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=spr\"><strong>Central Nervous System Lymphoma Pipeline Insights<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">Get comprehensive analysis of <\/span><span style=\"font-weight: 400;\">Central Nervous System Lymphoma<\/span><span style=\"font-weight: 400;\"> pipeline therapies and key companies including <\/span><strong>Shandong New Time Pharmaceutical, AstraZeneca, Bristol-Myers Squibb, Janseen, Celgene,<\/strong><span style=\"font-weight: 400;\"> among others.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=spr\"><strong>Cyclin-Dependent Kinase Inhibitor Pipeline Insights<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">Get comprehensive analysis of <\/span><span style=\"font-weight: 400;\">Cyclin-Dependent Kinase Inhibitor<\/span><span style=\"font-weight: 400;\">\u00a0 pipeline therapies and key companies including <\/span><strong>Roche,\u00a0 Teijin Pharma, Cyclacel Pharmaceuticals, Bayer Schering Pharma, Merck &#038; Co, Astex Therapeutics,<\/strong><span style=\"font-weight: 400;\"> among others.<\/span><span style=\"font-weight: 400;\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/consulting\/market-assessment-services?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=spr\"><strong>Get in touch with our Business executive for Competitive Insights, M&#038;A and Due Diligence<\/strong><\/a><strong> Services<\/strong><\/p>\n<p><span style=\"font-weight: 400;\">About<\/span><a href=\"https:\/\/www.delveinsight.com\/?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=spr\"> <strong>DelveInsight<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform<\/span><a href=\"https:\/\/www.pharmdelve.com\/?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=spr\"> <strong>PharmDelve<\/strong><span style=\"font-weight: 400;\">.<\/span><\/a><\/p>\n<p><a href=\"http:\/\/www.delveinsight.com\"><span style=\"font-weight: 400;\">www.delveinsight.com<\/span><\/a><\/p>\n<p><strong>Connect With Us at:<\/strong><\/p>\n<p><a href=\"https:\/\/www.linkedin.com\/company\/delveinsight-business-research-llp\/\"><strong>LinkedIn<\/strong><\/a> <strong>|<\/strong><a href=\"https:\/\/www.facebook.com\/delveinsightindia\/\"> <strong>Facebook<\/strong><\/a> <strong>|<\/strong><a href=\"https:\/\/twitter.com\/delve_insight\"> <strong>Twitter<\/strong><\/a><\/p>\n<div>\n<h3>Contact Information:<\/h3>\n<p>Contact Us\u00a0:<br \/> Sandeep Joshi\u00a0<br \/> info@delveinsight.com\u00a0<br \/> +1(919)321-6187\u00a0<\/p>\n<\/p>\n<\/div>\n<p>The post <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/\">Increasing incidence of hematological and genetic disorders in both developed and developing countries fuels the demand for Adeno-Associated Virus (AAV) Vectors in Gene Therapy<\/a> appeared first on <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\">Financial Market Brief<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline report provides in-depth analysis of the current clinical development landscape and growth prospects for Adeno-Associated Virus (AAV) Vectors in Gene Therapy. Some of the Crucial Highlights from the AAV Vectors in Gene Therapy Pipeline Report AAV particles are made up of single-stranded DNA encased in a [&hellip;]<\/p>\n<p>The post <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/\">Increasing incidence of hematological and genetic disorders in both developed and developing countries fuels the demand for Adeno-Associated Virus (AAV) Vectors in Gene Therapy<\/a> appeared first on <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/\">Financial Market Brief<\/a>.<\/p>\n<p> <a href=\"https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/\" class=\"more-link\">Continue Reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":291,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-122305","post","type-post","status-publish","format-standard","hentry","category-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Increasing incidence of hematological and genetic disorders in both developed and developing countries fuels the demand for Adeno-Associated Virus (AAV) Vectors in Gene Therapy - Business<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Increasing incidence of hematological and genetic disorders in both developed and developing countries fuels the demand for Adeno-Associated Virus (AAV) Vectors in Gene Therapy - Business\" \/>\n<meta property=\"og:description\" content=\"DelveInsight&rsquo;s Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline report provides in-depth analysis of the current clinical development landscape and growth prospects for Adeno-Associated Virus (AAV) Vectors in Gene Therapy. Some of the Crucial Highlights from the AAV Vectors in Gene Therapy Pipeline Report AAV particles are made up of single-stranded DNA encased in a [&hellip;] The post Increasing incidence of hematological and genetic disorders in both developed and developing countries fuels the demand for Adeno-Associated Virus (AAV) Vectors in Gene Therapy appeared first on Financial Market Brief. Continue Reading &rarr;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Business\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-19T19:30:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/07\/5353-new20logo-01-2.png\" \/>\n<meta name=\"author\" content=\"iCrowdNewswire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"iCrowdNewswire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/\",\"url\":\"https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/\",\"name\":\"Increasing incidence of hematological and genetic disorders in both developed and developing countries fuels the demand for Adeno-Associated Virus (AAV) Vectors in Gene Therapy - Business\",\"isPartOf\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/07\/5353-new20logo-01-2.png\",\"datePublished\":\"2021-07-19T19:30:00+00:00\",\"author\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\"},\"breadcrumb\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/#primaryimage\",\"url\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/07\/5353-new20logo-01-2.png\",\"contentUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/07\/5353-new20logo-01-2.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ipsnews.net\/business\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Increasing incidence of hematological and genetic disorders in both developed and developing countries fuels the demand for Adeno-Associated Virus (AAV) Vectors in Gene Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ipsnews.net\/business\/#website\",\"url\":\"https:\/\/ipsnews.net\/business\/\",\"name\":\"Business\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ipsnews.net\/business\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\",\"name\":\"iCrowdNewswire\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"caption\":\"iCrowdNewswire\"},\"sameAs\":[\"https:\/\/heymuse.com\/ips\"],\"url\":\"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Increasing incidence of hematological and genetic disorders in both developed and developing countries fuels the demand for Adeno-Associated Virus (AAV) Vectors in Gene Therapy - Business","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/","og_locale":"en_US","og_type":"article","og_title":"Increasing incidence of hematological and genetic disorders in both developed and developing countries fuels the demand for Adeno-Associated Virus (AAV) Vectors in Gene Therapy - Business","og_description":"DelveInsight&rsquo;s Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline report provides in-depth analysis of the current clinical development landscape and growth prospects for Adeno-Associated Virus (AAV) Vectors in Gene Therapy. Some of the Crucial Highlights from the AAV Vectors in Gene Therapy Pipeline Report AAV particles are made up of single-stranded DNA encased in a [&hellip;] The post Increasing incidence of hematological and genetic disorders in both developed and developing countries fuels the demand for Adeno-Associated Virus (AAV) Vectors in Gene Therapy appeared first on Financial Market Brief. Continue Reading &rarr;","og_url":"https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/","og_site_name":"Business","article_published_time":"2021-07-19T19:30:00+00:00","og_image":[{"url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/07\/5353-new20logo-01-2.png","type":"","width":"","height":""}],"author":"iCrowdNewswire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"iCrowdNewswire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/","url":"https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/","name":"Increasing incidence of hematological and genetic disorders in both developed and developing countries fuels the demand for Adeno-Associated Virus (AAV) Vectors in Gene Therapy - Business","isPartOf":{"@id":"https:\/\/ipsnews.net\/business\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/#primaryimage"},"image":{"@id":"https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/07\/5353-new20logo-01-2.png","datePublished":"2021-07-19T19:30:00+00:00","author":{"@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee"},"breadcrumb":{"@id":"https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/#primaryimage","url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/07\/5353-new20logo-01-2.png","contentUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/07\/5353-new20logo-01-2.png"},{"@type":"BreadcrumbList","@id":"https:\/\/ipsnews.net\/business\/2021\/07\/19\/increasing-incidence-of-hematological-and-genetic-disorders-in-both-developed-and-developing-countries-fuels-the-demand-for-adeno-associated-virus-aav-vectors-in-gene-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipsnews.net\/business\/"},{"@type":"ListItem","position":2,"name":"Increasing incidence of hematological and genetic disorders in both developed and developing countries fuels the demand for Adeno-Associated Virus (AAV) Vectors in Gene Therapy"}]},{"@type":"WebSite","@id":"https:\/\/ipsnews.net\/business\/#website","url":"https:\/\/ipsnews.net\/business\/","name":"Business","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipsnews.net\/business\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee","name":"iCrowdNewswire","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","caption":"iCrowdNewswire"},"sameAs":["https:\/\/heymuse.com\/ips"],"url":"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/122305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/users\/291"}],"replies":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/comments?post=122305"}],"version-history":[{"count":1,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/122305\/revisions"}],"predecessor-version":[{"id":122306,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/122305\/revisions\/122306"}],"wp:attachment":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/media?parent=122305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/categories?post=122305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/tags?post=122305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}